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Available online 24 November 2015Background: Cardiac mast cell (MC) proteases, chymase and tryptase, increase proliferation and collagen
synthesis in cultured cardiac ﬁbroblasts. However, the question as to why preventing individually the actions
of either protease prevents ﬁbrosis when both are released upon MC activation remains unanswered. Since
tryptase has the ability to activate MCs in noncardiac tissues via the protease-activated receptor-2 (PAR-2),
there is the possibility that its, in vivo, ﬁbrotic role is due to its ability to induce MC degranulation thereby
amplifying the release of chymase.
Methods: This study sought to delineate the interactions between tryptase and chymase in myocardial remodel-
ing secondary to transverse aortic constriction (TAC) for 5 weeks in male Sprague–Dawley rats untreated or
treated with either the tryptase inhibitor, nafamostat mesilate or MC membrane stabilizing drug, nedocromil
(n = 6/group). In addition, ventricular slices from 6 rat hearts were incubated with tryptase, tryptase plus
nafamostat mesilate or the chymase inhibitor chymostatin for 24 h.
Results and conclusion: The results indicate the presence of PAR-2 on MCs and that tryptase inhibition and
nedocromil prevented TAC-induced ﬁbrosis and increases in MC density, activation, and chymase release.
Tryptase also signiﬁcantly increased chymase concentration in ventricular slice culture media, which was
prevented by the tryptase inhibitor. Hydroxyproline concentration in culture media was signiﬁcantly increased
with tryptase incubation as compared to the control group and the tryptase group incubated with nafamostat
mesilate or chymostatin. We conclude that tryptase contributes to TAC-induced cardiac ﬁbrosis primarily via
activation of MCs and the ampliﬁed release of chymase.& Ana
bia,
icki).
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Cardiac mast cells (MCs) have been identiﬁed as being causally in-
volved in the development of left ventricular (LV) ﬁbrosis associated
with hypertension [1,2]. They produce and release a wide variety of
proteases, cytokines, growth factors, vasoactive agents and other
biologically active mediators that are capable of mediating tissue
remodeling. In particular the proteases, chymase and tryptase, have
been shown to increase cultured cardiacﬁbroblast proliferation and col-
lagen synthesis [3,4]. Both are stored in a macromolecular complex in
MC cytoplasmic secretory granules and are released upon MC activa-
tion. Chymase promotes cardiac ﬁbroblast proliferation and collagen
synthesis via the TGF-β1/Smad pathway [3] while tryptase increases
cardiac ﬁbroblast proliferation and collagen synthesis via a mechanismtomy, University of South
SC 29209, United States.
ility and freedom frombias
Ltd. This is an open access articlinvolving the activation of protease-activated receptor 2 (PAR-2) and
subsequent induction of extracellular signal-regulated kinase signaling
[4,5]. Chymase inhibition was also reported to markedly attenuate
myocardial ﬁbrosis in the cardiomyopathic hamster [6], in dogs with
tachycardia induced heart failure [7], in the spontaneously hypertensive
rat [8], and in rats with transverse aortic constriction [9]. Similarly,
blockade of tryptase with a PAR-2 antagonist prevented ﬁbrosis in the
spontaneously hypertensive rat (SHR) heart [4]. However, these ﬁnd-
ings raise the question as to how preventing individually the actions
of either chymase or tryptase can prevent ﬁbrosis when both are re-
leased upon activation of MCs and both have been shown to mediate
cardiac ﬁbrosis. Given the fact that tryptase has the ability to activate
mast cells in noncardiac tissues via PAR-2 [10], there is the possibility
that its primary, in vivo, ﬁbrotic role may be via its ability to induce
mast cell degranulation thereby inducing the release of chymase.
Thus, this study sought to determine the extent to which tryptase
inﬂuences MC activation and myocardial chymase levels to delineate
the interactions betweenMC tryptase and chymase inmyocardial extra-
cellular matrix remodeling. The results indicate that the elevation ine under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tryptase-induced MC activation. Accordingly, the resulting ﬁbrosis was
directly related to tryptase-induced increases in chymase.
2. Methods
2.1. Animals
The protocol was approved by the Institution's Animal Care and Use
Committee andwas in compliancewith theNational Institutes of Health
Guidelines for the Care and Use of Laboratory Animals. Seven week old
male Sprague–Dawley rats, purchased from Harlan Laboratories, were
housed under standard environmental conditions and maintained
on a rodent diet and tap water ad libitum. Anesthesia for all surgical
procedures was achieved by an intraperitoneal injection of ketamine
(100 mg/kg) and xylazine (10 mg/kg) and postoperative analgesia
was maintained by the administration of buprenorphine hydrochloride
(0.025 mg/kg). At the experimental endpoint and under deep anesthe-
sia, a blood samplewas obtained and the heart and lungswere removed
and the wet weights of the LV+ septum and lungs were obtained. The
basal portion of the LVwasﬁxed in 10% formalin for histological analysis
and the apical portion was snap frozen in liquid nitrogen and stored at
−80 °C for subsequent analysis. The tibia length (TL) was measured
and used to normalize tissue weights.
2.2. Transverse aortic constriction and drug treatment
TAC or sham surgical procedure was performed as described else-
where [11]. Brieﬂy, a medial skin incision from the neck to the upper
chest was made and a cranial portion of the sternum opened. ThisFig. 1. Transverse aortic constriction (TAC) or sham surgery was performed in 7-week-old ma
(NM) initiated 3 days prior to surgery. Group differences in the ratio of left ventricular weigh
are presented in panels A and B, respectively. Representative microscopic images of myocardi
(×100 magniﬁcation). All values are mean ± SEM, N = 6; *P b 0.05 vs. Sham, +P b 0.05 vs. TAapproach allowed for the direct visualization of the transverse aorta
without having to enter the pleural space. The transverse aorta between
the right innominate and left carotid artery was constricted to the out-
side diameter of a 22-gauge needle using 6–0 silk suture. Sham surgery
was performed without banding the aorta. Three days prior to creation
of TAC, groups of rats either remained untreated or were administered
nedocromil (Ne), a mast cell stabilizing drug, or nafamostat mesilate
(NM), a potent and selective tryptase inhibitor. Ne was delivered at a
rate of 30 mg kg−1 day−1 via time release pellets (Innovative Research
of America, Sarasota, FL) that were implanted subcutaneously [12]. NM
wasdissolved in sterilewater and administrated by a daily intraperitone-
al injection (5 mg/kg/day) [13]. These treatments were continued until
animal sacriﬁce. The animals were grouped as follows: sham operated
(Sham, n = 6) and transverse aortic constriction with no treatment
(TAC, n = 6), with Ne treatment (Ne-TAC, n = 6) and with NM treat-
ment (NM-TAC, n = 6). Five weeks after TAC or sham surgery, the rats
were sacriﬁced and tissue and blood sampleswere collected as described
above.
2.3. Transthoracic echocardiography
On the day of sacriﬁce, the rats were sedatedwith isoﬂurane (~1.5%)
and LV size and function were evaluated echocardiographically using a
Vevo 770 High-Resolution Imaging System with a 37.5-MHz high-
frequency linear transducer (VisualSonics Inc. Toronto, ON, Canada).
LV internal diameter and posterior wall thickness at end-systole and
-diastole were measured from short-axis M-mode images recorded at
the papillary muscle level. Fractional shortening and ejection fraction
were calculated using VisualSonics' Measurement Software standard
formulae.le rats with continuous administration of either nedocromil (Ne) or nafamostat mesilate
t (LV) to tibia length (TL) and interstitial collagen volume fraction 5 weeks after surgery
um stained with collagen-speciﬁc picrosirius red are depicted for the 4 groups in panel C
C and Ne-TAC.
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Six, eightweek oldmale Sprague–Dawley rats were deeply anesthe-
tized and a median sternotomy performed aseptically and the heart
removed andwashed in cold sterile saline. The LV plus septumwas sep-
arated from the rest of the heart and ﬁlled with 2.5% agarose and then
placed into a metal cylinder containing agarose. The LV was sliced
perpendicular to the long axis (250 to 300 μm in thickness) using a
Brendel/Vitron Tissue Slicer (Vitron Organ Slicing Tech., Tuscon, AZ).
To determine the effects of tryptase on cardiac mast cell activation
and collagen production, 16 to 20 LV slices from each heart were
randomly divided into four groups with four or more slices per well:
1) culture media (Waymonth +10% FBS) alone (Con); 2) culture
media with tryptase (Try, 100 mU/ml, Promega, Madison, WI) [14,15];
3) culture media with tryptase and NM (Try-NM, 10 μg/ml) [16]; and
4) culture media with tryptase and chymostatin (Try-Ch, 10 μM, MP
Biomedicals, Solon, OH) [17]. NM and Ch were added to the culture
media 30 min prior to addition of tryptase. After 24 h of incubation
(37 °C, 95% O2, and 5% CO2), the slices from each well were weighed,Fig. 2. Transverse aortic constriction (TAC) or sham surgerywas performed in 7-week-oldmale
prior to TAC surgery. The changes in LV posterior wall thickness (LVPW) and internal diameter
tion (EF) and fractional shortening (FS), determined by echocardiography, are shown in panel A
muscle level and photomicrographs of left ventricle (LV) coronal section, respectively, 5 weeks
All values are mean ± SEM, N = 6, *P b 0.05 vs. Sham.snap frozen and stored at−80 °C. The culture media from each well
was aliquoted, snap frozen and stored at−80 °C.
2.5. Histology
Formalin-ﬁxed LV tissue was embedded in parafﬁn and 5 μm thick
cross sections were stained with collagen-speciﬁc picrosirius red [18].
Twenty microscopic ﬁelds (100×) per section devoid of perivascular
collagen were imaged. Interstitial collagen volume fraction (CVF)
was determined from these images using ImageProPlus 6.0. (Media
Cybernetics, Inc., Bethesda,MD) andwas expressed as percent of collagen
stained area in the ﬁeld. LV MCs were stained with toluidine blue [19].
MC density in the section was calculated by dividing the number of
MCs per section by the section area measured with a calibrated imaging
densitometer (Bio-Rad). If one or more extruded granules were visible
adjacent to the MC, the cell was considered to be degranulating [20].
The degranulatingMCswere counted and divided by the total MC popu-
lation in the section to yield the percent degranulation. To localize PAR-2
on cardiac MCs, formalin-ﬁxed LV tissue sections from sham rat heartsratswith administration of either nedocromil (Ne) or nafamostatmesilate (NM) three days
(LVID) at the end-diastole (LVPWd, LVIDd,) and -systole (LVPWs, LVIDs), LV ejection frac-
. Shown in panel B and C are the representative LV echocardiograms taken at the papillary
post TAC or sham surgery. Panel D shows the ratio of lungweight (LW) to tibia length (TL).
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system (SCBT Inc., Santa Cruz, CA), which was followed by alcian blue
staining, a speciﬁc stain for MCs [17].
2.6. Western blot, ELISA and hydroxyproline measurement
Total protein from LV tissue was extracted using RIPA buffer and a
protease inhibitor cocktail (Pierce, Rockford, IL). Protein samples were
fractionated by SDS-PAGE and then transferred to nitrocellulose
membranes. The membranes were incubated with corresponding
primary antibodies against tryptase (abcam, Cambridge MA), and
GAPDH (SCBT Inc., Santa Cruz, CA), subsequently incubated with HRP-
conjugated secondary antibodies and detected with the ECL Detection
Kit (Thermo Scientiﬁc, Rockford, IL). The protein expression was quan-
tiﬁedwith Image J (NIH) and adjusted to GAPDH. Plasma tryptase levels
were measured using a rat MC tryptase ELISA kit (Mybiosource, San
Diego, CA) and chymase levels in plasma and culture media were
measured using a rat chymase ELISA kit (Uscn Life Science Inc., Wuhan,
PRC) according to themanufacturer's instructions. For themeasurement
of chymase, culture media was concentrated by using centrifugal ﬁlter
devices (Millipore, Tullagreen, Carrigtwohill Co Cork IRL). Hydroxypro-
line levels in culture media and tissue were measured using a hydroxy-
proline colorimetric assay kit (Biovision, Milpitas CA).
2.7. Statistical analysis
Results are presented as mean ± SEM. For comparison between
groups, one-way analysis of variance (ANOVA) was performed,
followed by the Tukey post-hoc test. Statistical signiﬁcance was set at
a P value b0.05.
3. Results
3.1. Tryptase inhibition prevented TAC-induced LV hypertrophy and ﬁbrosis
The effect of the tryptase inhibitor, nafamostat mesilate (NM), and
MC stabilizing compound nedocromil (Ne) on LV hypertrophy and ﬁ-
brosis is shown in Figs. 1 and 2. Included in Fig. 2 are representative
LV echocardiograms taken at the papillary muscle level (Fig. 2B) and
photomicrographs of LV coronal sections (Fig. 2C) 5 weeks post TAC
or sham surgery. NM was able to signiﬁcantly prevent the increase in
LV weight normalized to tibial length (Fig. 1A) and end-diastolic and
end-systolic posterior wall thickness (Fig. 2A) that occurred followingFig. 3. Transverse aortic constriction (TAC) or sham surgery was performed in 7-week-old ma
(NM) started 3 days prior to surgery. Five weeks after surgery, left ventricle tissue tryptase p
were measured using an ELISA kit (panel C). All values are mean ± SEM, N = 6; *P b 0.05 vs. S5 weeks of transverse aortic constriction in the untreated rats. While
Ne had no effect on TAC-induced hypertrophy, both NM and Ne were
able to prevent the cardiac ﬁbrosis secondary to TAC (Fig. 1B). There
were no signiﬁcant group differences in echocardiographically mea-
sured LV internal diameter, ejection fraction, and fractional shortening
(Fig. 2A), and normalized lung weight (Fig. 2D) indicating that LV
systolic function remained compensated in the untreated and treated
TAC groups.
3.2. Tryptase inhibition prevented TAC-increased myocardial and plasma
tryptase protein content
Myocardial tryptase protein content for the 4 groups, as determined
by Western blot (Fig. 3A), is depicted in Fig. 3B. Also, the plasma
tryptase levels, which are assumed to include the tryptase released
from myocardial MCs, are shown in Fig. 3C. As can be seen, TAC signiﬁ-
cantly increased myocardial tryptase protein content and plasma
tryptase. MC stabilization by Ne prevented the TAC-induced elevation
of plasma tryptase level but had no effect on tissue tryptase protein con-
tent. However, tryptase inhibition by NM prevented both TAC-induced
increases in myocardial tryptase protein content and plasma tryptase,
which indicates the presence of a positive feedback loop of mast cell
tryptase in the myocardium that was enhanced by TAC.
3.3. TAC-induced myocardial mast cell activation was prevented by
tryptase inhibition
As shown in Fig. 4, LVMCdensity anddegranulationwere signiﬁcantly
increased in the TAC group compared with that in the Sham group.
Plasma chymase levels, which are assumed to include the chymase
released from myocardial MCs, were also signiﬁcantly increased in the
TAC group relative to the Sham group. The TAC-induced increases in LV
MC density and degranulation and plasma chymase levels did not occur
in the Ne-TAC group. Interestingly, the TAC-induced increases did not
occur in NM-TAC group either, indicating tryptase inhibition prevented
TAC-induced increases in cardiacMC density and activation and chymase
release.
3.4. tryptase simulated chymase release and increased collagen production
in cultured LV tissue slices
The results presented in Figs. 3 and 4 indicate that TAC-induced
increases in myocardial tryptase are responsible for increases in MCle rats with continuous administration of either nedocromil (Ne) or nafamostat mesilate
rotein content was measured by Western blot (panels A and B). Plasma tryptase levels
ham; +P b 0.05 vs. TAC and Ne-TAC; #P b 0.05 vs. TAC.
Fig. 4. Transverse aortic constriction (TAC) or sham surgery was performed in 7-week-old
male rats with continuous administration of either nedocromil (Ne) or nafamostat
mesilate (NM) started 3 days prior to TAC surgery. Five weeks after surgery, LV mast cell
(MC) density and degranulation were measured using toluidine blue stained tissue
(panels A and B, respectively). Plasma chymase levels were measured using an ELISA kit
(panel C). All values are mean ± SEM; N = 6; *P b 0.05 vs. Sham; +P b 0.05 vs. TAC.
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ability of tryptase to activate myocardial MCs, the presence of the
tryptase receptor, PAR-2 on myocardial MCs was examined in sham
rat hearts (Fig. 5A–C) and in LV tissue slices incubated with tryptase
plus NMor Ch (Fig. 5D–F). PAR-2was found to be localized to interstitial
cells (Fig. 5B) and myocardial MCs by double staining for PAR-2 and
MCs (Fig. 5C); PAR-2 density was greater in myocardial MCs than in
the other interstitial cells. Tryptase signiﬁcantly increased chymase
concentration in LV tissue culture media, which was prevented by the
tryptase inhibitor, NM, but not by chymase inhibitor, Ch, (Fig. 5D),
verifying the ability of tryptase to activate myocardial MCs to release
chymase. The effects of tryptase on collagen production were also
examined in LV tissue culture slices and media by the measurement of
hydroxyproline, a nonproteinogenic amino acid found only in collagen
and elastin in mammals. There were no group differences in hydroxy-
proline concentration in the slices (Fig. 5F). However, it was signiﬁcant-
ly increased in the culturemedia of the group incubatedwith tryptase as
compared to the control group and the Try groups incubated with NM
and Ch (Fig. 5E).4. Discussion
Tryptase, which is almost exclusively found inMCs [21], is associated
with the pathogenesis of ﬁbrosis such as that occurring in the lung [22],
kidney [23], and skin [24]. Recently, it has been reported that tryptase
causes ﬁbrosis in the hypertensive heart as well as a PAR-2-mediated
increase in collagen production in cultured cardiac ﬁbroblasts [4,5]. Al-
ternatively the othermajorMCprotease, chymase, also causes increased
collagen synthesis by cultured cardiac ﬁbroblasts [3]. However, the fact
that the in vivo inhibition of either tryptase or chymase results in the
prevention of ﬁbrosis, raises the question as to whether the ﬁbrotic
actions of these two MC proteases are part of a common pathway.
Given the fact that tryptase has been shown to activate MCs in noncar-
diac tissue via the PAR-2 receptor [10], its primary, in vivo, ﬁbrotic role
may be via its ability to induceMC degranulation thereby increasing the
synthesis/release of chymase. Indeed, this is the major ﬁnding of this
study.
TAC for ﬁve weeks induced LV hypertrophy and ﬁbrosis along with
increases in cardiac MC density, degranulation and release of tryptase
and chymase. Treatment of TAC animals with the MC membrane
stabilizing agent, Ne, prevented cardiacﬁbrosis, but not LV hypertrophy,
corroborating our previous report using the SHRmodel [5]which repre-
sents a distinctly different model of pressure overload. Further, tryptase
inhibition by NM, an extremely potent and selective tryptase inhibitor
[25], prevented the TAC-induced LVﬁbrosis, indicating thatMC tryptase
played a crucial role in the adverse TAC-induced LV myocardial
remodeling. This ﬁts with our previous report that blockade of PAR-2
prevented cardiac ﬁbrosis in the SHR [4]. Tryptase inhibition also atten-
uated MC tryptase synthesis and release. Furthermore, inhibition of
tryptase prevented the TAC-induced increase inMCdensity and degran-
ulation, resulting in reduced MC chymase release. This provides
evidence that the effects of tryptase on cardiac ﬁbrosis may be via its
regulation of chymase. Tryptase-stimulated histamine release has
been reported to occur in the tonsils, lungs and skin [26–28], which in
the case of skin was PAR-2 mediated [28]. The fact that we have
shown herein the presence of PAR-2 on cardiac MCs strongly suggest
that, in vivo, tryptase activates cardiac MCs via PAR-2 to enhance MC
density and chymase release in an autocrine fashion.
To verify the in vivo observation that tryptase-stimulated MC
chymase release in TAC rats and to determine the extent to which
chymase mediates the effects of tryptase on myocardial ﬁbrosis, cul-
tured LV tissue slice experiments were performed. In this preparation,
myocardial cells retain their 3-D structural integrity, intercellular inter-
actions and extracellular attachments and the myocardial response to
perturbations is solely intrinsic in that it is void of factors, such as circu-
lating inﬂammatory cells, cytokines, variations in the neuro-hormonal
background, and variations in preload, afterload and contractility. Also,
multiple perturbations on tissue from an individual heart are possible
thereby minimizing biological variability. Incubating LV tissue slices
with exogenous tryptase resulted in MC chymase release into the cul-
ture media, conﬁrming that tryptase induces MC release of chymase in
the myocardial tissue. This was prevented by the tryptase inhibitor
but not by a chymase inhibitor, indicating that chymase does not have
autocrine actions on MCs, at least in regard to chymase release.
Most importantly, incubation of LV slices with tryptase increased the
synthesis of hydroxyproline (a surrogate marker of collagen) which
was prevented by tryptase inhibition and, importantly, by chymase in-
hibition. These ﬁndings represent direct evidence that the pro-ﬁbrotic
actions of tryptase in the LV are mediated by chymase.
In an earlier study, we reported the following: myocardial tryptase
content was increased in SHR; blockade of PAR-2 preventedmyocardial
ﬁbrosis in SHR; and tryptase increased cultured cardiac ﬁbroblast
conversion to the myoﬁbroblast phenotype and collagen production
via PAR-2 [5]. Collectively, these observations led us to conclude that
tryptase contributed to myocardial ﬁbrosis via activation of PAR-2 on
cardiac ﬁbroblasts [4]. However, given the ﬁndings reported herein
Fig. 5. Panel A shows mast cells stained with mast cell speciﬁc alcian blue. panel B illustrates single immunostaining of PAR-2 (arrow heads) localization of PAR-2 in LV interstitial cells.
Panel C demonstrates the presence of the tryptase receptor, PAR-2, onmyocardial mast cells that were double stainedwith immunostaining for protease-activated receptor 2 (PAR-2) and
alcian blue formast cell (arrowheads in panel C). LV tissue slices from8-week-oldmale ratswere cultured inWaymonthmedia for 24 h untreated (Con) or treatedwith tryptase (Try), Try
plus nafamostat mesilate (NM-Try) or Try plus chymostatin (Ch-Try). Chymase concentrations in culture media were measured using an ELISA kit (panel D). Hydroxyproline concentra-
tions in culture media and the tissue slices are shown in panels E and F, respectively. All values are mean ± SEM; N = 6; *P b 0.05 vs. Con; +P b 0.05 vs. Try.
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that the antiﬁbrotic effects of PAR-2 blockade in SHR may primarily
have been attributed to the blockade of PAR-2 onMCs.While the contri-
bution of PAR-2 on ﬁbroblasts remains a possibility, our previous
cultured ﬁbroblast studies did not detect collagen synthesis in response
to tryptase (100 mU/mL) until after 72 h of treatment [5], as opposed
to the 24 h of tryptase (100 mU/mL) incubation of LV tissue slices
studied herein. We have reported collagen synthesis by isolated
cardiac ﬁbroblasts at 24 h [4], however, that required 1000 mU/mL
(~1000 ng/mL) of tryptase, 10 times higher than that used in the LV
slice experiments and ~140 times higher than the plasma level of
tryptase (~7 ng/ml) determined in TAC rats in the present study.
Although, it is important to note that tryptase concentration may be
substantially higher at the local level where MCs are degranulating.
Interestingly though, isolated cardiac ﬁbroblasts do proliferate in
response to tryptase (100 mU/mL) after 24 h. Thus, tryptase activation
of PAR-2 on ﬁbroblasts may be important in initiating their proliferation,
whereas PAR-2 initiation of chymase release byMCsmay be the stimulus
for collagen production by ﬁbroblasts. Chymase can contribute toﬁbrosis
by the formation of angiotensin II and activation of transforming growth
factor (TGF)-β1.
To the best of our knowledge, there are no speciﬁc tryptase inhibi-
tors available. Although NM has been found to be an extremely potent
and selective tryptase inhibitor [25], it is also capable of inhibiting avariety of other serine proteases at higher concentrations. Thus a
possible shortcoming to the study lies in the fact that we do not know
whether trypsin and other serine proteases associated with ﬁbrosis
were inhibited byNMat the dose used in the present and previous stud-
ies [13]. However, there has been no speciﬁc report to indicate that NM
is capable of inhibiting chymase. Therefore, it is highly unlikely that the
antiﬁbrotic effects of NM in the present study were related to its inhibi-
tion of chymase.5. Perspectives
As summarized in Fig. 6, the results herein delineate the interactions
between MC tryptase and chymase involved in hypertension-related
cardiac ﬁbrosis. TAC-increased myocardial tryptase and chymase
release from MCs. The released tryptase further activated MCs and
chymase release thus amplifying the effects of MCs on TAC-induced
myocardial ﬁbrosis. Tryptase inhibition prevented TAC-induced myo-
cardial ﬁbrosis primarily by preventing activation ofMCs and the subse-
quent increase in released chymase. The fact that chymostatin
completely prevented tryptase-induced collagen synthesis resolves
the issue as to why in vivo inhibition of either tryptase or chymase re-
sults in the prevention of ﬁbrosis when both are released from activated
MCs. Moreover, the involved pathway is such that treatment with a
Fig. 6. A schematic summary of the results. Mast cell activators are released frommyocardial cells in response to TAC. Upon activation, cardiacmast cells release tryptase and chymase into
the interstitium. Released tryptase acts in an autocrine fashion to activate mast cells and thus further increase tryptase and chymase release. Nedocromil prevents mast cell tryptase and
chymase releasewhile nafamostatmesilate prevents tryptase-inducedmast cell activation. The fact that chymostatin completely prevents tryptase-induced collagen synthesis resolves the
issue as to why in vivo inhibition of either tryptase or chymase results in prevention of ﬁbrosis when both are released from activated MCs.
22 J. Li et al. / IJC Metabolic & Endocrine 10 (2016) 16–23tryptase or chymase inhibitor or a MC membrane stabilizing drug will
prevent pressure overload-induced ﬁbrosis.
Source of funding
This work was supported in part by the National Heart, Lung and
Blood Institute of the National Institutes of Health (grant #s R21-HL-
59981 to JSJ and R00-HL-093215 to SPL).
Conﬂict(s) of interest/disclosure(s)
No conﬂicts of interest to disclose.
Novelty and signiﬁcance
In this study the interactions between MC tryptase and chymase
involved in hypertension-related cardiac ﬁbrosis are delineated. The
results resolve the issue as to why in vivo inhibition of either tryptase
or chymase results in the prevention of ﬁbrosis when both are released
from activated mast cells. That is tryptase contributes to hypertension-
induced cardiac ﬁbrosis primarily via PAR-2 activation of cardiac mast
cells causing the ampliﬁed release of chymase, which in turn stimulates
ﬁbroblast collagen production.
References
[1] J.S. Janicki, G.L. Brower, S.P. Levick, The emerging prominence of the cardiac mast
cell as a potent mediator of adverse myocardial remodeling, Methods Mol. Biol.
1220 (2015) 121–139.
[2] S.P. Levick, G.C. Meléndez, E. Plante, J.L. McLarty, G.L. Brower, J.S. Janicki, Cardiac
mast cells: the centrepiece in adverse myocardial remodelling, Cardiovasc. Res. 89
(2011) 12–19.
[3] X.Y. Zhao, L.Y. Zhao, Q.S. Zheng, J.L. Su, H. Guan, F.J. Shang, X.L. Niu, Y.P. He, X.L. Lu,
Chymase induces proﬁbrotic response via transforming growth factor-beta
1/Smad activation in rat cardiac ﬁbroblasts, Mol. Cell. Biochem. 310 (2008) 159–166.[4] J.L.McLarty, G.C.Meléndez, G.L. Brower, J.S. Janicki, S.P. Levick, Tryptase/Protease-ac-
tivated receptor 2 interactions induce selective mitogen-activated protein kinase
signaling and collagen synthesis by cardiac ﬁbroblasts, Hypertension 58 (2011)
264–270.
[5] S.P. Levick, J.L. McLarty, D.B. Murray, R.M. Freeman, W.E. Carver, G.L. Brower, Cardiac
mast cells mediate left ventricular ﬁbrosis in the hypertensive rat heart, Hypertension
53 (2009) 1041–1047.
[6] S. Takai, D. Jin, M. Sakaguchi, S. Katayama, M.Muramatsu, M. Sakaguchi, E. Matsumura,
S. Kim,M.Miyazaki, A novel chymase inhibitor, 4-[1-([bis-(4-methyl-phenyl)-methyl]-
carbamoyl)3-(2-ethoxy-benzyl)-4-oxo-azetidine-2-yloxy]-benzoic acid (BCEAB),
suppressed cardiac ﬁbrosis in cardiomyopathic hamsters, J. Pharmacol. Exp. Ther. 305
(2003) 17–23.
[7] T. Matsumoto, A. Wada, T. Tsutamoto, M. Ohnishi, T. Isono, M. Kinoshita, Chymase
inhibition prevents cardiac ﬁbrosis and improves diastolic dysfunction in the
progression of heart failure, Circulation 107 (2003) 2555–2558.
[8] W. Liu, J. Chen, T. Xu, W. Tian, Y. Li, Z. Zhang, W. Li, Qiliqiangxin improves cardiac
function in spontaneously hypertensive rats through the inhibition of cardiac
chymase, Am. J. Hypertens. 25 (2012) 250–260.
[9] J. Li, S. Jubair, J.S. Janicki, Estrogen inhibitsmast cell chymase release to prevent pressure
overload-induced adverse cardiac remodeling, Hypertension 65 (2015) 328–334.
[10] M.R. D'andrea, C.J. Rogahn, P. Andrade-Gordon, Localization of protease-activated
receptors−1 and −2 in human mast cells: indications for an ampliﬁed mast cell
degranulation cascade, Biotech Histochem 75 (2000) 85–90.
[11] Y. Xia, K. Lee, N. Li, D. Corbett, L. Mendoza, N.G. Frangogiannis, Characterization of
the inﬂammatory and ﬁbrotic response in a mouse model of cardiac pressure
overload, Histochem. Cell Biol. 131 (2009) 471–481.
[12] H. Lu, G.C. Meléndez, S.P. Levick, J.S. Janicki, Prevention of adverse cardiac remodel-
ing to volume overload in female rats is the result of an estrogen-altered mast cell
phenotype, Am. J. Physiol. Heart Circ. Physiol. 302 (2012) H811–H817.
[13] T. Sendo, Y. Itoh, T. Goromaru, T. Sumimura, M. Saito, K. Aki, T. Yano, R. Oishi, A po-
tent tryptase inhibitor nafamostat mesilate dramatically suppressed pulmonary
dysfunction induced in rats by a radiographic contrast medium, Br. J. Pharmacol.
138 (2003) 959–967.
[14] S.J. Compton, J.A. Cairns, S.T. Holgate, A.F. Walls, The role of mast cell tryptase in
regulating endothelial cell proliferation, cytokine release, and adhesion molecule
expression: tryptase induces expression of mRNA for IL-1b and IL-8 and stimulates
the selective release of IL-8 from human umbilical vein endothelial cells, J. Immunol.
161 (1998) 1939–1946.
[15] S. He, M.D. Gaça, A.F. Walls, A role for tryptase in the activation of humanmast cells:
modulation of histamine release by tryptase and inhibitors of tryptase, J Pharmacol
Exp Ther 286 (1998) 289–297.
[16] E. Sand, A. Themner-Persson, E. Ekblad, Mast cells reduce survival of myenteric
neurons in culture, Neuropharmacology 56 (2009) 522–530.
23J. Li et al. / IJC Metabolic & Endocrine 10 (2016) 16–23[17] J. Li, H. Lu, E. Plante, G.C. Meléndez, S.P. Levick, J.S. Janicki, Stem cell factor is respon-
sible for the rapid response inmature mast cell density in the acutely stressed heart,
J. Mol. Cell. Cardiol. 53 (2012) 469–474.
[18] G.C. Meléndez, J.L. McLarty, S.P. Levick, Y. Du, J.S. Janicki, G.L. Brower, Interleukin 6
mediates myocardial ﬁbrosis, concentric hypertrophy, and diastolic dysfunction in
rats, Hypertension 56 (2010) 225–231.
[19] G.L. Brower, A.L. Chancey, S. Thanigaraj, B.B. Matsubara, J.S. Janicki, Cause and effect
relationship between myocardial mast cell number and matrix metalloproteinase
activity, Am. J. Physiol. Heart Circ. Physiol. 283 (2002) H518–H525.
[20] W. Li, T. Guo, D. Liang, Y. Sun, W.S. Kingery, J.D. David Clark, Substance P signaling
controls mast cell activation, degranulation, and nociceptive sensitization in a rat
fracture model of complex regional pain syndrome, Anesthesiology 116 (2012)
882–895.
[21] M. Castells, A.A. Irani, L.B. Schwartz, Evaluation of human peripheral blood
leukocytes for mast cell tryptase, J. Immunol. 138 (1987) 2184–2189.
[22] I.A. Akers, M. Parson, M.R. Hill, M.D. Hollenburg, S. Sanjar, G.J. Laurent, R.J. McAnulty,
Mast cell tryptase stimulates human lung ﬁbroblast proliferation via protease
activate receptor-2, Am. J. Physiol. Lung Cell. Mol. Physiol. 278 (2000) L193–L201.
[23] A.E. Sirvent, C. Gonzalez, R. Enriquez, J. Fernandez, I. Millan, X. Barber, F. Amoros,
Serum tryptase level and markers of renal dysfunction in a population with chronic
kidney disease, J. Nephrol. 23 (2010) 282–290.[24] M.B. Frungieri, S. Weidinger, V. Meineke, F.M. Kohn, A. Mayerhofer, Proliferative action
of mast-cell tryptase is mediated by PAR2, COX2, prostaglandins, and PPAR_: possible
relevance to humanﬁbrotic disorders, ProcNatl Acad Sci US A99 (2002) 15072–15077.
[25] S. Mori, Y. Itoh, R. Shinohata, T. Sendo, R. Oishi, M. Nishibori, Nafamostat mesilate is
an extremely potent inhibitor of human tryptase, J. Pharmacol. Sci. 92 (2003)
420–423.
[26] S. He, M.D.A. Gaca, A.F. Walls, A role for tryptase in the activation of human mast
cells: modulation of histamine release by tryptase and inhibitors of tryptase, J
Pharmacol Exp Ther 286 (1998) 289–297.
[27] S. He, A. Aslam, M.D. Gaça, Y. He, M.G. Buckley, M.D. Hollenberg, A.F. Walls, Inhibi-
tors of tryptase as mast cell-stabilizing agents in the human airways: effects of
tryptase and other agonists of proteinase-activated receptor 2 on histamine release,
J Pharmacol Exp Ther 309 (2004) 119–126.
[28] C. Moormann, M. Artuc, E. Pohl, G. Varga, J. Buddenkotte, N. Vergnolle, R. Brehler,
B.M. Henz, S.W. Schneider, T.A. Luger, M. Steinhoff, Functional characterization
and expression analysis of the proteinase-activated receptor-2 in human cutaneous
mast cells, J. Invest. Dermatol. 126 (2006) 746–755.
